FDG-PET and Circulating HPV in Patients With Cervical Cancer Treated With Definitive Chemoradiation (II)

Recruiting now NCT03853915

Run by University Health Network, Toronto · for 18 and older · Women

What this study is about

Nearly all cervical cancers are caused by the human papilloma virus (HPV), which can be detected in cancer tissue by laboratory tests. There is evidence that the virus can also be detected from a blood sample to monitor the effects of treatment. Previous studies have shown that a special test called 18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET-CT) at 3 months after treatment may predict survival in cervical cancer. The purpose of this study is to see how well the FDG-PET Scan and blood tests for HPV can detect leftover cervical cancer cells after treatment. This study is not a particular form of treatment and patients will receive standard of care treatment.

Who can join (things the study team will check)

✅ You may be able to join if…

Histologically confirmed squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma of the cervix, FIGO stage IB-IVA
3.1.2 Planned for radical radiotherapy and concurrent cisplatin chemotherapy.
3.1.3 Age ≥ 18 years.

🚫 You may not be able to join if…

Evidence of distant metastases (suspicious paraaortic nodes below the renal vessels allowed if they will be encompassed within the radiation field)
Patients who have received any anticancer treatment for their cervical cancer.
Other cervical cancer tumor histologies (e.g. small cell, serous)
Contraindications to 18FDG PET-CT
Contraindication to radiotherapy (e.g. severe Crohn's disease)
Contraindication to chemotherapy (e.g. non-reversible renal failure)
History of another invasive malignancy, except for non-melanoma skin cancer or tumors curatively treated with no evidence of disease for ≥ 5 years.
Known pregnancy or lactating

Where this trial is running

University Health Network, The Princess Margaret, Toronto, Ontario, Canada

Who to contact

Kathy Han, MD · 416 946 4501 · kathy.han@rmp.uhn.ca

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT03853915.

Open the interactive checklist for this trial →

Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.

Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.